Therapy of refractive skin ulcer by using platelet rich plasma

Therapy of refractive skin ulcer by using platelet rich plasma - Treatment of ulcer by PRP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023969

Enrollment

Registered

2016-09-07

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decubitus and refractive skin ulcer(excepting cosmetic surgery)

Interventions

administration(once a week, Max 8 times) dosage(1mL of ten folds concentrated plate-rich plasma)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To meet all of the following conditions. 1) no effect on FGF-2 or occulutive negative pressure treatment for 28 days. 2) case of reject following therapy a. amptation b. skin graft c. other surgical approach 3) ill systemic condition for operation 4) patient who can collect the venous blood for PRP production 5) over 20 years old 6) patient who can take a informed consent

Exclusion criteria

Exclusion criteria: If any of the following items. 1) patients who can not control the infection of the wound surface. 2) the wound surface (ulcer) with malignancy 3) significant anemia (both men and women less than Hb 7g / dL) 4) leukemia 5) aplastic anemia 6) thrombocytopenia 7) blood coregration abnormality 8) no compliance 9) no agreement

Design outcomes

Primary

Measure	Time frame
wound heeling with reepithelization after 8 weeks.	—

Countries

Japan

Contacts

Public ContactHajime Inoue

St.Marianna University School of Medecine Dept. of Plastic and Reconstructive Surgery, Div. of Stem Cell Medecine

h2inoue@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026